
Contents

1 Introduction –

Positron Emission Tomography: Past and Present 1

1.1	Survey	1
	Physical and Biochemical Fundamentals	2
	PET in National and International Medical Care Systems	2
1.2	Technological Variants and Developments . . .	4
	Coincidence PET vs. Dedicated PET	4
	Differentiated PET Evaluation	4
	Radiotherapeutic Tools	5
	PET/CT – a New Key Technology	5
	Influence of PET/CT on PET	5
	Studies Dealing with the Cost Efficiency of PET Alone	6
	PET/CT or Comparison of Co-Registered Findings?	6
	“Standard” (CARE)-CT and PET/CT	6
	PET/MRI?	6
	American Joint Committee on Cancer	7
	PET Screening in Japan and Taiwan	7
1.3	Increased FDG Uptake Due to Physiological and Technical Factors	7
1.4	References	8

2 Fundamentals

THOMAS BEYER. 11

2.1	Preface	11
	Positron Emission Tomography (PET)	11
	Radioisotopes and PET Tracers	12
	Coincidence Measurement and Quantification .	13
	PET Measurement Results and Reconstruction .	14
	PET Scanners and Scintillation Detectors . . .	16
2.2	Combined PET/CT	18
	Retrospective Image Fusion	18
	The PET/CT Prototype	18
	CT-Based Attenuation Correction	20
	Commercialization of PET/CT	21
	New Technical Developments in PET/CT . . .	23
	PET/CT Acquisition Protocols	29
	Sources of Errors and Optimization Options . .	30
	Radiation Protection Aspects	37
2.3	Conclusion	40
2.4	References	40

3 Pneumology 43

3.1	Bronchial Carcinoma (BC)	43
3.2	Significance of FDG-PET in Diagnostic and Therapeutic Management	44
	Critical Evaluation of Diagnosis Management .	45
3.3	Guidelines for ¹⁸ F-FDG-PET Indications	45
3.4	Technical and Biochemical Factors	46
	Is Coincidence PET Equivalent to Full-Ring PET?	46
	PET as Metabolism and Proliferation Marker. .	46
	Innovative Radiopharmacy	46
3.5	Special PET Indications	47
	False-Negative PET	47
	False-Positive PET	47
	How Useful Is Integrated PET/CT?	48
3.6	SCLC (Small-Cell Lung Cancer)	48
3.7	Pleural Processes	48
	Malignant Pleural Tumours (Mesothelioma) . .	49
	Imaging Methods	49
3.8	Case Studies	50
	Patient 1 Scar Carcinoma of the Lung	50
	Patient 2 Pneumonia	52
	Patient 3 Lymph Node Metastases of a Squamous Cell Carcinoma	54
	Patient 4 Metastasized Bronchial Carcinoma .	56
	Patient 5 Round Focus in the Lung	58
	Patient 6 Metastasized Bronchial Carcinoma .	60
	Patient 7 Metastasized Adenocarcinoma in the Left Lower Lobe of the Lung	61
	Patient 8 Downstaging of a Squamous Cell Carcinoma of the Lung	62
	Patient 9 Preoperative Staging of a Bronchial Carcinoma	64
	Patient 10 Pleural Carcinosis after Pneumectomy	66
	Patient 11 Recurrence of a Brain Metastasis . .	69
	Patient 12 Pleural Mesothelioma	71
	Patient 13 Prevention of Non-Curative Thoracic Surgery	73
	Patient 14 Upstaging of a Bronchial Carcinoma	76
	Patient 15 Bilateral Metastases of an NSCLC in the Suprarenal Glands	79
3.9	References	82

4 Gastroenterology	85
4.1 Introduction	86
Molecular Strategy	87
Metabolic Influencing Factors	88
PET Screening?	88
Incidentally Detected Lesions (IDL)	88
4.2 Oesophageal Carcinoma	88
PET in Diagnosis Management of Oesophageal Carcinoma	88
4.3 Gastric Carcinoma	90
MALT Lymphomas	90
4.4 Colorectal Carcinomas	90
Treatment	91
Status of PET	91
PET/CT as the Optimum	93
PET Indications	93
Limitations of PET	94
Artefacts	94
FDG-PET	94
Alternative and Adjuvant Markers	94
Synopsis	95
4.5 Liver and Biliary Tract Carcinomas	95
4.6 Gastrointestinal Stromal Tumours	95
4.7 Pancreas Carcinomas	96
Imaging	96
Curative Treatment	97
New Gene-Based Treatment Strategies	97
Indications	97
DGN Classes, Consequences	97
Impact of SUVs on Survival Time	97
False-Negative/-Positive PET Findings	97
Pancreas NETs (Neuroendocrine Tumours)	98
4.8 Neuroendocrine Tumours (NETs) of the Gastrointestinal Tract	98
Carcinoids	98
Conventional Diagnostics	98
NET Spectrum	99
Biochemistry	99
High Secretors	99
Low (Non-)Secretors	99
Limitations of PET	99
4.9 Case Studies	100
Patient 1 Oesophageal Carcinoma	100
Patient 2 Lymph Node Metastasis of an Oesophageal Carcinoma	103
Patient 3 Downstaging of an Oesophageal Carcinoma	105
Patient 4 Carcinoma of the Head of the Pancreas	107
Patient 5 Metastasized Carcinoma of the Head of the Pancreas	110
Patient 6 Carcinoma of the Body of the Pancreas	112
Patient 7 Hepatocellular Carcinoma with Multiple Metastases	114
Patient 8 Gastric Carcinoma	117
Patient 9 Leiomyoma of the Stomach	118
Patient 10 Follow-Up of an Adenocarcinoma of the Stomach	121
Patient 11 Staging of an Adenocarcinoma of the Stomach	123
Patient 12 Staging of a Carcinoma of the Corpus of the Stomach	124
Patient 13 Lymph Node Metastasis from Gastric Carcinoma	126
Patient 14 Extended Metastatic Spread to the Liver from Adenocarcinoma of the Stomach	128
Patient 15 Caecum Carcinoma	130
Patient 16 Carcinoma of the Colon Ascendens	132
Patient 17 T1 Carcinoma of the Colon	134
Patient 18 Adenocarcinoma of the Sigmoid Colon	136
Patient 19 Liver Metastasis of a Colon Carcinoma	138
Patient 20 Lymphoma Conglomerate Following Colon Carcinoma	140
Patient 21 Lung Metastasis Following Colon Carcinoma	142
Patient 22 Pulmonary, Hepatic and Lymphogenic Metastatic Spread Following Sigmoid Carcinoma	144
Patient 23 Metastasized Sigmoid Carcinoma	146
Patient 24 Peritoneal Carcinosis and Ascites Following Sigmoid Carcinoma	148
Patient 25 Lung Metastasis Following Sigmoid Carcinoma	150
Patient 26 Liver Metastasis Following Sigmoid Carcinoma	153
Patient 27 Lymph Node Metastasis Following Sigmoid Carcinoma	156
Patient 28 Metastatic Spread to the Liver Following Rectal Carcinoma	158
Patient 29 Liver and Lung Metastases Following Rectal Carcinoma	160
Patient 30 Rectal Carcinoma with Lymph Node Metastases	163
Patient 31 Suprarenal and Lung Metastases Following Rectal Carcinoma	166
Patient 32 Lung and Bone Metastases Following Rectal Carcinoma	168
Patient 33 Suprarenal Metastasis of a Rectal Carcinoma	169
Patient 34 Restaging of a Rectal Carcinoma	172
Patient 35 Suprarenal and Lung Metastases Associated with Rectal Carcinoma	174
Patient 36 Restaging of a Rectal Carcinoma	176
Patient 37 Local Recurrence and Liver Metastases of a Rectal Carcinoma	178
Patient 38 Extended Metastatic Spread of a Mesenterial Conglomerate Tumour	181
Patient 39 GIST Tumour with Liver Involvement	183
Patient 40 Malignoma in the Left Epigastric Region	184

Patient 41	GIST, Metastasis at the Greater Curvature of the Stomach. . .	186
Patient 42	Tumour Recurrence with Status Post GIST of the Stomach. . .	187
Patient 43	Therapy Response Follow-Up Examination Post GIST Resection. . .	189
Patient 44	Therapy Follow-Up in the Case of GIST	193
4.10	References	200

5 Gynaecology 205

5.1	Introduction	206
	The Importance of Nuclear Medical Methods	206
5.2	Breast Cancers	206
	Mammography	207
	Tumour Markers	208
	CT and MRI.	208
	¹⁸ F-Fluoride	209
	SPECT	209
	Sentinel Node Scintigraphy (SNS).	209
	Positron Emission Tomography	209
	Preoperative Axillary Staging	210
	Extra-Axillary Metastases	211
	Treatment Monitoring	211
	Potentials and Limitations of PET	211
	Special Neuro-Oncological Problems/Pitfalls. . .	212
	PET Screening?	212
	Risk Stratification	212
	PET/CT.	212
	Assessment of the Bone Status	212
	¹⁸ F-Fluoride PET	212
	Diagnostic Imaging of the Breast: Indications . .	212
5.3	Ovarian Cancer.	213
	Tumour Types	213
	Conventional Diagnostics	213
	PET	213
5.4	Peritoneal Cancer (PC)	215
5.5	Cervical Cancer.	215
	PET Diagnostics	215
5.6	Case Studies.	216
Patient 1	Lymph Node Metastasis with Status Post Carcinoma of the Right Breast and Ovarian Carcinoma on Both Sides	216
Patient 2	Inflammatory Breast Cancer	218
Patient 3	Breast Cancer with Osseous Metastases	220
Patient 4	Preoperative Staging of a Breast Cancer	222

Patient 5	Restaging of a Breast Cancer	224
Patient 6	Restaging of a Breast Cancer	226
Patient 7	Confirmation of the Diagnosis "Breast Cancer"	228
Patient 8	Psammoma	230
Patient 9	Ovarian Cancer	232
Patient 10	Restaging of an Ovarian Cancer . . .	234
Patient 11	Therapy Response of a Metastasized Ovarian Cancer	236
Patient 12	Metastasized Cervical Cancer	238
Patient 13	Bone Metastasis of a Corpus Uteri Cancer	240
Patient 14	Trophoblastic Tumour	242
Patient 15	Malignant Ovarian Cyst	244
Patient 16	Peritoneal Carcinosis Due to Ovarian Cancer	245
Patient 17	Metastasized Endometrial Carcinoma	248
Patient 18	Exclusion of Metastatic Spread of an Endometrial Carcinoma.	250
Patient 19	Therapy Control in Case of Ovarian Carcinoma	252
Patient 20	Lymph Node and Bone Metastases in Case of Ovarian Carcinoma	254
Patient 21	Local Recurrence of Breast Cancer .	256
Patient 22	Restaging of a Breast Cancer after Chemotherapy	259
Patient 23	Restaging of a Breast Cancer after Rise in Tumour Marker Level	261
Patient 24	Primary Staging of a Breast Cancer .	262
Patient 25	Restaging of a Breast Cancer after Reduction in Tumour Marker Level. .	264
Patient 26	Pre-Therapeutic Staging of a Breast Cancer	267
Patient 27	Restaging of a Metastasized Breast Cancer.	269
Patient 28	Detection of Metastases by PET/CT with Negative Conventional Imaging .	271
Patient 29	Therapy Control of a Metastasized Breast Cancer	275
Patient 30	Therapy Control of a Metastasized Breast Cancer	276
Patient 31	Evaluation of Radiotherapy Response in Case of Metastasized Breast Cancer	279
Patient 32	Restaging of a Breast Cancer	283
Patient 33	Restaging of a Breast Cancer Revealing a Fracture Risk in the C6 Vertebral Body	285
Patient 34	Restaging of a Breast Cancer with PET/CT Providing Much More Detailed Information	287
Patient 35	Pleural Carcinosis in a Patient with Breast Cancer	290
Patient 36	Lung Metastases of a Breast Cancer .	292
Patient 37	Bone Metastases of a Breast Cancer .	294
Patient 38	Male Patient with Metastasized Breast Cancer	296

5.7	References	298
------------	-----------------------------	------------

6 Urology	303	Patient 26 First Diagnosis of a Prostate Carcinoma	361
6.1 Introduction	303	Patient 27 Response Evaluation of a Prostate Carcinoma	362
6.2 Renal Malignancies	304	6.9 References	363
Introduction	304		
Diagnostics	304		
6.3 Adrenal Tumours	305		
Imaging Diagnostics	305		
6.4 Bladder Carcinoma	305		
Status of PET	306		
6.5 Prostate Carcinoma	306		
Introduction	306		
Diagnostics	306		
Treatment	309		
Status of Individual Imaging Methods	309		
6.6 Germ Cell Tumours	313		
Introduction	313		
PET Study Situation	314		
6.7 Penis Carcinoma	315		
6.8 Case Studies	316		
Patient 1 Malignoma of the Base of the Bladder	316		
Patient 2 Malignoma of the Posterior Wall of the Bladder	318		
Patient 3 Metastasis in the Suprarenal Gland on the Left Side	320		
Patient 4 Metastasis in the Suprarenal Gland on the Right Side	322		
Patient 5 Metastasized Renal Cell Carcinoma	325		
Patient 6 Restaging after Chemotherapy	327		
Patient 7 Restaging after Tumour Nephrectomy	330		
Patient 8 Recurrence after Tumour Nephrectomy	332		
Patient 9 Metastasized Prostate Carcinoma	334		
Patient 10 Metastasized Prostate Carcinoma	336		
Patient 11 Restaging of a Prostate Carcinoma	338		
Patient 12 Lymph Node Metastasis of a Prostate Carcinoma	340		
Patient 13 First Diagnosis of a Prostate Carcinoma	342		
Patient 14 Restaging of a Prostate Carcinoma	343		
Patient 15 Restaging of a Prostate Carcinoma	345		
Patient 16 Therapy Control for Metastasized Prostate Carcinoma	347		
Patient 17 Staging of a Prostate Carcinoma	349		
Patient 18 Local Recurrence of a Prostate Carcinoma	351		
Patient 19 Lymph Node Metastasis of a Prostate Carcinoma	352		
Patient 20 Lymph Node Metastases of a Prostate Carcinoma	353		
Patient 21 First Diagnosis of a Prostate Carcinoma	354		
Patient 22 Prostatitis	355		
Patient 23 Prostatitis	356		
Patient 24 Prostatitis	357		
Patient 25 Restaging of a Prostate Carcinoma	359		
		7 Head and Neck Region	369
		7.1 Head and Neck Tumours	369
		¹⁸ F-FDG-PET	371
		FDG-PET Pitfalls	373
		PET Indications	373
		7.2 Thyroid Carcinomas	374
		¹⁸ F-FDG-PET	375
		7.3 Case Studies	378
		Patient 1 CUP Tumour	378
		Patient 2 Tumour Recurrence of an Atypical Laryngeal Carcinoid	380
		Patient 3 Restaging of an Oropharyngeal Carcinoma	381
		Patient 4 Hypopharyngeal Carcinoma	384
		Patient 5 Restaging after Multiple Carcinoma	386
		Patient 6 Auricle Carcinoma	388
		Patient 7 Tonsillar and Laryngeal Carcinoma and Carcinoma of the Base of the Tongue	390
		Patient 8 Recurrence of a Squamous Cell Carcinoma of the Tongue	392
		Patient 9 Tonsillar Carcinoma	394
		Patient 10 Restaging of a Small-Cell Carcinoma of the Left Principal Nasal Cavity	396
		Patient 11 Recurrence of a Vocal Cord Carcinoma	400
		Patient 12 Cerebral Metastatic Spread of a Bronchial Carcinoma	402
		Patient 13 Cystadenocarcinoma of the Lacrimal Sac	405
		Patient 14 Alzheimer's Disease	406
		Patient 15 Oligodendroglioma on the Left Side	408
		Patient 16 Low-Malignancy Brain Tumour on the Left Side	410
		Patient 17 Hypophyseal Metastasis	413
		7.4 References	415
		8 Dermatology	419
		8.1 Malignant Melanoma (MM)	419
		Introduction	419
		Significance of PET	421
		Pitfalls	421
		PET Indications	421
		8.2 Case Studies	422
		Patient 1 Malignant Melanoma of the Right Thigh	422
		Patient 2 Recurrent Melanoma	424

Patient 3	Metastasized Melanoma	426
Patient 4	Choroidal Melanoma	427
Patient 5	Metastasized Amelanotic Melanoma	428
8.3	References	433

9 Lymphomas 435

9.1	Introduction	435
9.2	Diagnosis	436
	Imaging Methods	436
	FDG-PET	437
	Response Evaluation	437
	Comparison of FDG-PET, ⁶⁷ Ga and CT	438
	Autologous Stem Cell Therapy	438
	PET/CT Restaging	438
	Artefacts	439
	Other Problems	439
	PET Indications	439
9.3	Case Studies	440
Patient 1	Follicular Non-Hodgkin's Lymphoma	440
Patient 2	Metastasized Non-Hodgkin's Lymphoma	442
Patient 3	B-Cell Lymphoma in the Hypopharynx	444
Patient 4	B-Cell Lymphoma	446
Patient 5	Lymphogranulomatosis, Nodular Sclerosis	448
Patient 6	T-Cell Lymphoma of the Cervical Lymph Tract	449
Patient 7	B-Cell Lymphoma	451
Patient 8	Restaging of Hodgkin's Disease	454
Patient 9	Recurrent Hodgkin's Lymphomas	459
Patient 10	Chronic Lymphatic Leukaemia	461
Patient 11	Restaging of the Multiple Myeloma	461
9.4	References	463

10 Oncological Orthopaedics 465

10.1	Introduction	465
10.2	Significance of PET	465
	PET Tracers	466
	PET Indications	466
10.3	Case Studies	467
Patient 1	Sweat Gland Carcinoma	467
Patient 2	Haemangioendothelioma	470
Patient 3	Chondrosarcoma	473
Patient 4	Medullary Osteosarcoma	476
Patient 5	Clear Cell Sarcoma	478
Patient 6	Rhabdomyosarcoma	480
Patient 7	Rhabdomyosarcoma of the Left Thigh	482
Patient 8	Embryonal Rhabdomyosarcoma	484
10.4	References	486

11 Paediatric Oncology 487

11.1	Introduction	487
	Changes in the Range of Clinical Indications	488
11.2	Lymphomas in Childhood	488
	Staging, Restaging, Prognosis and Therapy Control	488
11.3	Oncological Orthopaedics in Childhood	488
11.4	Neuroblastomas	488
11.5	Malignant Melanomas	488
11.6	Nesidioblastosis (Congenital Hyperinsulinism)	489
11.7	Case Studies	490
Patient 1	Status Post Osteogenous Sarcoma	490
Patient 2	Status Post Mastitis	491
Patient 3	Embryonal Rhabdomyosarcoma	492
Patient 4	Focal Congenital Hyperinsulinism	494
Patient 5	Focal Congenital Hyperinsulinism	496
Patient 6	Focal Congenital Hyperinsulinism	498
Patient 7	Diffuse Congenital Hyperinsulinism	500
Patient 8	Focal Congenital Hyperinsulinism	502
Patient 9	Focal Congenital Hyperinsulinism	504
Patient 10	Focal Congenital Hyperinsulinism	506
Patient 11	Langerhans Cell Histiocytosis	508
Patient 12	Langerhans Cell Histiocytosis, Staging and Restaging	510
11.8	References	514

12 CUP Tumours 515 (Cancer of Unknown Primary)

12.1	Introduction	515
12.2	Significance of PET	516
	Cancer of Unknown Primary:	
	Indication for PET/CT?	516
	Studies Available	516
	Artefacts, Pitfalls and Metabolic Heterogeneity	516
12.3	Case Studies	517
Patient 1	Carcinoma of the Base of the Tongue	517
Patient 2	Carcinoma of the Base of the Tongue	518
Patient 3	Oropharyngeal Carcinoma	520
Patient 4	Cholangiocarcinoma	523
Patient 5	Pancreatic Carcinoma	526
Patient 6	Carcinoma of the Head of the Pancreas	528
Patient 7	Mamma Carcinoma	530
Patient 8	CUP Tumour	533
Patient 9	Mamma Carcinoma	536
Patient 10	Carcinoma of the Base of the Tongue	538
Patient 11	Bronchial Carcinoma	540
Patient 12	Bronchial Carcinoma	542
12.4	References	544

13 Pitfalls	545	14 Radiotherapeutic Aspects	625
13.1 Testicular Carcinoma and Other Primary Tumours	546	14.1 Introduction	625
Universal Organ Spectrum of SPT	546	14.2 PET-Assisted Radiotherapy Planning	625
13.2 Physiological Accumulation of FDG	547	14.3 Advantages of PET/CT Integration	626
13.3 False Positive FDG Accumulations in the Oncological Sense	547	14.4 Fundamentals Governing the Use of PET/CT Data for Radiotherapy – Bits and Bytes and DICOM	626
13.4 Artefacts Due to Technical Factors	547	14.5 Case Studies	630
13.5 False Negative PET Findings	547	Patient 1 Prostate Cancer	630
13.6 Case Studies Secondary Tumours	548	Patient 2 Oropharyngeal Cancer	632
Patient 1 Inflammatory Carcinoma of the Breast and Papillary Carcinoma of the Inner Genital Tract	548	Patient 3 Breast Cancer	634
Patient 2 Carcinoma in Situ with Osteoplastic Metastases 10 years later	551	Patient 4 Prostate Cancer	636
Patient 3 Recurrence of a Sigmoid Carcinoma, Compression of the Left Ureter	554	Patient 5 Squamous Cell Carcinoma of the Oral Cavity	638
Patient 4 Cervical Carcinoma and Rectal Carcinoma	556	Patient 6 Bronchial Cancer	640
Patient 5 Mamma Carcinoma and Colon Carcinoma	558	14.6 References	643
Patient 6 Mamma Carcinoma and Sigmoid Carcinoma	560	15 Nuclear Cardiology	645
Patient 7 Thymoma	561	– the Situation in Europe	
Patient 8 Prostate Carcinoma and Colon Carcinoma	564	15.1 Introduction	645
Patient 9 Renal Cell and Prostate Carcinoma	566	Development of Nuclear Cardiology and the Present State	645
Patient 10 Prostate Carcinoma and Colon Carcinoma	568	Molecular Cardiac Imaging	647
Patient 11 Carcinoma in Situ of the Rectum and Bronchial Carcinoma	570	Fusion Imaging	649
Patient 12 Non-Hodgkin's Lymphoma and Bronchial Carcinoma	574	SPECT and SPECT/CT	650
Patient 13 Mamma Carcinoma and Bronchial Carcinoma	577	MRI and PET/MRI	652
Patient 14 Coecum, Bronchial and Renal Carcinoma	579	15.2 Cardiac PET/CT	652
Patient 15 Mamma, Cervical and Rectal Carcinoma	583	Coronary Sclerosis	652
Patient 16 Parotid and Colon Carcinoma	586	Diabetes Mellitus and Coronary Sclerosis	654
13.7 Case Studies		Plaque Imaging	655
Physiologically Increased Uptake	589	Perfusion	656
Patient 17–21	589	Vitality	657
13.8 Case Studies		Radiation Exposure and Contrast Medium Safety	657
Non-Oncological Increased Uptake of Inflammatory Genesis	593	Artefacts	658
Patient 22–31	593	Invasive Diagnostics, Treatment and Treatment Monitoring	658
13.9 Case Studies		Prevention	661
Artefacts	611	Remarks on the Catalogue for Further Training for the Specialization in Nuclear Medicine	661
Patient 32–39	611	15.3 Case Studies	663
13.10 References	622	Patient 1 Mild CHD	663
		Patient 2 Status Post Revascularization	666
		Patient 3 Status Post Anterior Infarction and Sextuple Bypass	668
		Patient 4 Surprise Finding of Stem Stenosis	672
		15.4 Reference	676

16 Cardiac PET and PET/CT	687	16.4 Vascular Inflammation and Atherosclerosis . .	709
– the Situation in the USA		16.4.1 Large Vessel Vasculitis	709
16.1 Introduction	687	16.4.2 Atherosclerosis and Plaque Imaging	711
16.2 Coronary Artery Disease	687	16.5 Future Developments	714
Imaging with PET	688	16.6 References	714
Accuracy of PET and PET/CT Stress-Rest			
Myocardial Perfusion Imaging	693		
Advantages of Myocardial Perfusion Imaging			
with PET	696		
Hybrid PET/CT Myocardial Perfusion Imaging			
in Coronary Artery Disease	697		
16.3 Myocardial Viability	698		
Concepts and Pathophysiology	699		
Assessment of Myocardial Viability	699		
Imaging of Myocardial Perfusion			
and Metabolism	701		
Clinical Implications of			
Perfusion Metabolism Imaging	705		
PET/CT vs. Stand-Alone PET	707		
Clinical Indications of			
Perfusion Metabolism Imaging	708		
		17 Future Trends: Molecular PET	721
		17.1 Technical Potential and	
		Software Optimization	721
		17.2 Molecular PET	722
		Tumour Vitality and	
		Glucose Transporters (GLUT)	722
		Therapeutic and Diagnostic Potential	722
		17.3 Final Remark	723
		17.4 References	724
		Subject Index	727

Oncologic and Cardiac PET/CT-Diagnosis
An Interdisciplinary Atlas and Manual
Mohnike, W.; Hör, G.; Schelbert, H.R. (Eds.)
2008, XV, 739 p. With DVD., Hardcover
ISBN: 978-3-540-74090-2